Lansoprazole
Lansoprazole. Irreversible H+/K+-ATPase inhibitor. CYP2C19 + CYP3A4 substrate. Available OTC; commonly co-administered with NSAIDs to mitigate… Oral half-life 2.2 h.
Irreversible H+/K+-ATPase inhibitor. CYP2C19 + CYP3A4 substrate. Available OTC; commonly co-administered with NSAIDs to mitigate gastric ulcers.
PK: F 0.85 was a CROSS-DOSE AVERAGE of a stated "the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation"; the 30 mg value is stored and is dose-specific. Half-life corrected to 2.24 h. V 18 L IS ITS OWN STUDY SUBJECT COUNT — nine homozygous extensive metabolisers plus nine poor metabolisers — and the identical pair (ka 1.5, V 18) sits on CEPHALEXIN, a beta-lactam sharing no chemistry, no mass and no clearance route, so the seed almost certainly originated here and was copied. THE STORED HALF-LIFE WAS ALSO A GENOTYPE SUBGROUP: 1.96 h in extensive against 4.21 h in poor metabolisers, with 3.4-fold exposure and 4.6-fold clearance differences. EFFECT IS DECOUPLED ABOUT TENFOLD, stated in one sentence of one study: "the t1/2z values of lansoprazole and the 2 metabolites were ~2 to 2.5 hours, while the acid-inhibitory effect lasted >24 hours". ka 1.5 dropped; absorption is enteric-coat lagged, and no numeric lag exists for this drug, so the omeprazole figure must not be borrowed.
Pharmacokinetics
- Oral — t½ 2.2 h · F 91%
Sources: PMID:8803522, PMID:24683233, PMID:15301728